SD-rat에 KIOM-MA128을 경구 투여 한 후 혈장 중 Matrine의 약물 동태

Pharmacokinetic Study of Matrine in SD-rat after Oral Administration of KIOM-MA128

KIOM-MA128 is a novel Korean herbal medicine with anti-atopic, anti-inflammatory and anti-asthmatic effects. This article presents the first pharmacokinetic study on KIOM-MA128. The purpose of this study was to characterize a pharmacokinetic characteristic of matrine, a potential marker of KIOM-MA128, in rats using population pharmacokinetic model. 1, 2 and 8 g/kg of KIOM-MA128 were administered to rats orally and plasma concentrations of matrine was determined by HPLC-MS/MS. Non-compartmental analysis (NCA) was performed using Phoenix？？ and pharmacokinetic model was built using NONMEM？？. This model was validated with internal validation which is visual predictive check (VPC) and bootstrap. The NCA result of matrine showed that Cmax was 294.24, 552.22 and 868.65 ng/ml, AUCinf was 1273.05, 2724.76 and 9743.25 ng · hr/ml and Tmax was 1, 1.3 and 2.3 hr for the doses of 1, 2, and 8 g/kg, respectively. The rat plasma concentrations were described very well with one-compartment model. Pharmacokinetic model for matrine was successfully developed and evaluated. Finally, our model is helpful to understand pharmacokinetic characteristic of KIOM-MA128.